Table 1.

Baseline characteristics and treatment choices of PDAC patients diagnosed by EUS-guided FNA

Stage I (n = 16)Stage II (n = 33)Stage III (n = 18)Stage IV (n = 28)P
Age, y72 ± 1268 ± 1268 ± 1166 ± 100.28
Mass size, mm24 ± 728 ± 742 ± 1040 ± 170.244
CA 19-9, u/mL (median, range)131 (5–2, 498)230 (6–>10,000)190 (5–>10,000)473 (5–>10,000)0.56
Normal CA 19-9 (≤35 u/mL)12% (2/16)11% (3/27)30% (4/13)10% (2/20)
miR-10b (a.u.)5,759 ± 2,3355,947 ± 2,2486,672 ± 2,0606,759 ± 2,3060.33
Low miR-10b (<5,000 a.u.)50% (8/16)45% (15/33)22% (4/18)36% (10/28)
Treatment choices
 Surgery alone, %0000
 Surgery + adjuvant chemotherapy1/162/3300
 Chemoradiotherapy, no surgery4/1611/3310/180
 Chemoradiotherapy and surgery7/1615/332/180
 Palliative chemotherapy004/1819/28
 Best supportive care/unknown4/165/332/189/28
 Median survival, mo161283